Filing summary
Important identification note: The filing text is AVROBIO, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed March 25, 2019. It does not identify Tectonic Therapeutic, Inc. or report a standalone 2018 fourth quarter. The summary below reflects the filing provided.
Business context and reporting period
AVROBIO was a clinical-stage gene-therapy company developing ex vivo lentiviral treatments for rare diseases. Its lead candidate, AVR-RD-01, targeted Fabry disease; other programs addressed Gaucher disease, cystinosis and Pompe disease. The annual report covers the year ended December 31, 2018, with certain clinical and corporate updates through March 2019.
Financial results and liquidity
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $35.1 million | $15.2 million |
| General and administrative expense | $11.1 million | $3.2 million |
| Total operating expenses | $46.2 million | $18.4 million |
| Net loss | $46.4 million | $18.6 million |
| Net cash used in operating activities | $37.6 million | $16.4 million |
- Cash and cash equivalents were $126.3 million at year-end 2018, compared with $6.0 million a year earlier. Total current assets were $130.0 million and current liabilities $10.6 million.
- Cash, cash equivalents and restricted cash totaled $126.8 million at year-end. Investing activities used $1.8 million; financing activities provided $160.3 million, primarily from the IPO and Series B preferred-stock financing.
- The company reported no outstanding borrowings under its SVB facility; the undrawn facility expired October 31, 2018. Operating lease commitments totaled $4.9 million.
- Margins are not meaningful because the company had no product sales. Management estimated year-end cash would fund operations and capital expenditures into the second half of 2020, subject to assumptions; the notes also state cash was expected to cover at least 12 months from the filing date.
Material changes versus the prior year
Net loss increased by $27.7 million as operating expenses rose $27.9 million. R&D expense increased $19.9 million, reflecting expanded Fabry and Gaucher development, higher personnel and facility costs, and process-development activity. G&A expense rose $8.0 million, including public-company and staffing costs. Operating cash use increased $21.3 million. The June 2018 IPO generated approximately $104.0 million in net proceeds; January 2018 Series B financing generated approximately $58.3 million net.
Outlook, commentary, risks and unusual items
- Management expected continued significant losses and expense growth, with no product revenue anticipated in the near future. Additional capital will be required to advance development and commercialization; future financing may dilute shareholders or require less favorable terms.
- AVR-RD-01 was being evaluated in investigator-sponsored Phase 1 and company-sponsored Phase 2 studies. Early results showed increased AGA enzyme activity in a small number of patients and generally preliminary tolerability; the evidence was not confirmatory of efficacy or durability. The company planned U.S. Phase 2 site expansion in 2019.
- The company expected to begin dosing in Phase 1/2 studies of AVR-RD-02 and AVR-RD-04 in the second half of 2019; AVR-RD-03 remained in early preclinical development. These were forward-looking plans, not completed milestones.
- Planned platform changes included transition from LV1 to LV2, closed automated manufacturing and busulfan conditioning with therapeutic drug monitoring. Comparability, regulatory acceptance, execution and safety are significant uncertainties. Conditioning can cause cytopenias; busulfan also carries a potential secondary-malignancy concern noted in the filing.
- Material weaknesses in internal control over financial reporting remained unremediated at year-end, including issues with close and cash-disbursement controls; a further weakness involved accruals for R&D expenses. Disclosure controls were deemed ineffective. The filing also describes a 2017 cyber theft and a February 2019 vendor-invoice fraud loss; the amount of the latter is not stated in the provided text.
- Unusual items included a $2.0 million payment to UHN related to IPO dilution, a $235,000 impairment loss on leasehold improvements, and $1.3 million of Australian R&D tax credits recorded as an offset to R&D expense. No material legal proceedings were reported.
Important facts for investors to verify
- Confirm the intended issuer and period: the supplied filing is AVROBIO’s 2018 annual 10-K, not a Tectonic Therapeutic filing or a Q4-only report.
- Review the audited financial statements, cash-flow trend and assumptions behind management’s cash-runway estimate; assess likely financing needs and dilution.
- Check subsequent clinical-trial disclosures for patient numbers, follow-up duration, safety events and whether early biomarker results translate into clinical benefit.
- Track regulatory acceptance and comparability of LV2 and the automated manufacturing platform, and the safety and monitoring plan for busulfan conditioning.
- Follow remediation of the disclosed material weaknesses and controls over R&D accruals, payments and vendor fraud.